Eisai Inc., an oncology- and neurology-focused pharmaceutical company and the U.S. subsidiary of Eisai Co., Ltd., (based in Tokyo, Japan) announced today the relocation of its New Jersey-based headquarters to the technologically-advanced and cutting-edge ON3 (www.on3nj.com) property in Nutley, New Jersey.
August 11, 2020
· 3 min read